Citing data from the All India Institute of Medical Sciences (AIIMS) Delhi, the company said, 2.5 cases of AML occurred in about 1,00,000 people in India.
American pharmaceutical company AbbVie has marked its entry into the Indian cancer drugs segment with Venetoclax used to treat Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL).
AML is a rare and aggressive form of blood cancer with limited treatment options, a note from the company said. Venetoclax offers a novel approach by selectively targeting cancer cells in the blood and bone marrow, providing an option for patients, particularly those unable to undergo conventional intensive chemotherapy due to age or other health conditions, the company said, without divulging the price of the medicine.
Citing data from the All India Institute of Medical Sciences (AIIMS) Delhi, the company said, 2.5 cases of AML occurred in about 1,00,000 people in India. Venetoclax offers a “convenient oral dosing regimen”, the company said, supporting a more personalised approach to care, “enabling clinicians to tailor treatment to a patient’s health status and tolerance an important consideration in managing this aggressive form of blood cancer.”
Suresh Pattathil, Managing Director and General Manager, AbbVie India, said, “Our entry into oncology in India signifies more than the launch of a single medication; it reflects our overarching commitment to advancing cancer care.” Rahul Rathod, Medical Director, AbbVie outlined “distinct challenges” that India faced with AML, including “late diagnosis, limited access to advanced therapies, and a growing burden of the disease among ageing population.”
Published on April 21, 2025